Loading...

MeVis Medical Solutions

XTRA:M3V
Snowflake Description

Flawless balance sheet with outstanding track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
M3V
XTRA
€55M
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

MeVis Medical Solutions AG develops, markets, and sells software for analyzing and evaluating image data to equipment manufacturers of medical devices and providers of medical IT platforms in the United States and Europe. The last earnings update was 27 days ago. More info.


Add to Portfolio Compare Print
M3V Share Price and Events
7 Day Returns
-1.9%
XTRA:M3V
-1.3%
DE Healthcare Services
-1.8%
DE Market
1 Year Returns
-15.8%
XTRA:M3V
15.8%
DE Healthcare Services
-7.3%
DE Market
M3V Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
MeVis Medical Solutions (M3V) -1.9% -7.7% -4.3% -15.8% 25.2% 99.5%
DE Healthcare Services -1.3% 1.5% 26.5% 15.8% 37.6% 153.7%
DE Market -1.8% -0.3% 6.8% -7.3% 7.5% 6.9%
1 Year Return vs Industry and Market
  • M3V underperformed the Healthcare Services industry which returned 15.8% over the past year.
  • M3V underperformed the Market in Germany which returned -7.3% over the past year.
Price Volatility
M3V
Industry
5yr Volatility vs Market

M3V Value

 Is MeVis Medical Solutions undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of MeVis Medical Solutions to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for MeVis Medical Solutions.

XTRA:M3V Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.1%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for XTRA:M3V
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Healthcare Services Unlevered Beta Simply Wall St/ S&P Global 1.22
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.22 (1 + (1- 30%) (0%))
1.148
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.15
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.148 * 5.96%)
7.07%

Discounted Cash Flow Calculation for XTRA:M3V using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for MeVis Medical Solutions is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

XTRA:M3V DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 7.07%)
2019 6.60 Analyst x1 6.16
2020 4.00 Analyst x1 3.49
2021 2.90 Analyst x1 2.36
2022 2.33 Est @ -19.53% 1.78
2023 2.02 Est @ -13.6% 1.43
2024 1.83 Est @ -9.45% 1.21
2025 1.71 Est @ -6.55% 1.06
2026 1.63 Est @ -4.52% 0.94
2027 1.58 Est @ -3.09% 0.85
2028 1.55 Est @ -2.1% 0.78
Present value of next 10 years cash flows €20.07
XTRA:M3V DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= €1.55 × (1 + 0.23%) ÷ (7.07% – 0.23%)
€22.65
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €22.65 ÷ (1 + 7.07%)10
€11.44
XTRA:M3V Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €20.07 + €11.44
€31.52
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €31.52 / 1.82
€17.32
XTRA:M3V Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in XTRA:M3V represents 1.02649x of DB:M3V
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
1.02649x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (EUR) x Listing Adjustment Factor
= € 17.32 x 1.02649
€17.77
Value per share (EUR) From above. €17.77
Current discount Discount to share price of €31.00
= -1 x (€31.00 - €17.77) / €17.77
-74.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of MeVis Medical Solutions is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for MeVis Medical Solutions's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are MeVis Medical Solutions's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
XTRA:M3V PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in EUR €4.54
DB:M3V Share Price ** DB (2019-03-25) in EUR €30.2
Germany Healthcare Services Industry PE Ratio Median Figure of 5 Publicly-Listed Healthcare Services Companies 30.11x
Germany Market PE Ratio Median Figure of 423 Publicly-Listed Companies 18.2x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of MeVis Medical Solutions.

XTRA:M3V PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= DB:M3V Share Price ÷ EPS (both in EUR)

= 30.2 ÷ 4.54

6.65x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MeVis Medical Solutions is good value based on earnings compared to the DE Healthcare Services industry average.
  • MeVis Medical Solutions is good value based on earnings compared to the Germany market.
Price based on expected Growth
Does MeVis Medical Solutions's expected growth come at a high price?
Raw Data
XTRA:M3V PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 6.65x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
-35.8%per year
Europe Healthcare Services Industry PEG Ratio Median Figure of 12 Publicly-Listed Healthcare Services Companies 1.95x
Germany Market PEG Ratio Median Figure of 275 Publicly-Listed Companies 1.39x

*Line of best fit is calculated by linear regression .

XTRA:M3V PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 6.65x ÷ -35.8%

-0.19x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MeVis Medical Solutions earnings are not expected to grow next year, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on MeVis Medical Solutions's assets?
Raw Data
XTRA:M3V PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in EUR €19.07
DB:M3V Share Price * DB (2019-03-25) in EUR €30.2
Germany Healthcare Services Industry PB Ratio Median Figure of 7 Publicly-Listed Healthcare Services Companies 2.02x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.78x
XTRA:M3V PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= DB:M3V Share Price ÷ Book Value per Share (both in EUR)

= 30.2 ÷ 19.07

1.58x

* Primary Listing of MeVis Medical Solutions.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MeVis Medical Solutions is good value based on assets compared to the DE Healthcare Services industry average.
X
Value checks
We assess MeVis Medical Solutions's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check)
  5. MeVis Medical Solutions has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

M3V Future Performance

 How is MeVis Medical Solutions expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-35.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is MeVis Medical Solutions expected to grow at an attractive rate?
  • MeVis Medical Solutions's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 0.2%.
Growth vs Market Checks
  • MeVis Medical Solutions's earnings are expected to decrease over the next 1-3 years, this is below the Germany market average.
  • MeVis Medical Solutions's revenues are expected to decrease over the next 1-3 years, this is below the Germany market average.
Annual Growth Rates Comparison
Raw Data
XTRA:M3V Future Growth Rates Data Sources
Data Point Source Value (per year)
XTRA:M3V Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts -35.8%
XTRA:M3V Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts -9.6%
Germany Healthcare Services Industry Earnings Growth Rate Market Cap Weighted Average 8.1%
Europe Healthcare Services Industry Revenue Growth Rate Market Cap Weighted Average 7.7%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.4%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
XTRA:M3V Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
XTRA:M3V Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-09-30 13 4 3 1
2020-09-30 14 5 4 1
2019-09-30 16 8 2 1
XTRA:M3V Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-12-31 17 6 8
2018-09-30 17 6 7
2018-06-30 16 6 7
2018-03-31 17 7 4
2017-12-31 17 7 3
2017-09-30 19 7 6
2017-06-30 19 7 5
2017-03-31 18 6 7
2016-12-31 18 4 8
2016-09-30 16 7 7
2016-06-30 17 6 7
2016-03-31 16 7 6

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • MeVis Medical Solutions's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • MeVis Medical Solutions's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
XTRA:M3V Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from MeVis Medical Solutions Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

XTRA:M3V Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-09-30 1.46 1.46 1.46 1.00
2020-09-30 2.03 2.03 2.03 1.00
2019-09-30 0.95 0.95 0.95 1.00
XTRA:M3V Past Financials Data
Date (Data in EUR Millions) EPS *
2018-12-31 4.54
2018-09-30 3.94
2018-06-30 3.72
2018-03-31 2.44
2017-12-31 1.51
2017-09-30 3.09
2017-06-30 3.01
2017-03-31 3.66
2016-12-31 4.31
2016-09-30 3.95
2016-06-30 4.06
2016-03-31 3.54

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • MeVis Medical Solutions is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess MeVis Medical Solutions's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
MeVis Medical Solutions has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

M3V Past Performance

  How has MeVis Medical Solutions performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare MeVis Medical Solutions's growth in the last year to its industry (Healthcare Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • MeVis Medical Solutions's year on year earnings growth rate has been positive over the past 5 years.
  • MeVis Medical Solutions's 1-year earnings growth exceeds its 5-year average (201.6% vs 12.6%)
  • MeVis Medical Solutions's earnings growth has exceeded the DE Healthcare Services industry average in the past year (201.6% vs 72.8%).
Earnings and Revenue History
MeVis Medical Solutions's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from MeVis Medical Solutions Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

XTRA:M3V Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 16.69 8.27 0.58
2018-09-30 16.76 7.17 0.60
2018-06-30 16.48 6.78 0.33
2018-03-31 17.02 4.43 0.49
2017-12-31 17.29 2.74 0.62
2017-09-30 18.54 5.62 0.59
2017-06-30 18.62 5.47 0.57
2017-03-31 17.97 6.66 0.55
2016-12-31 17.63 7.85 0.56
2016-09-30 16.17 7.20 0.55
2016-06-30 16.55 7.39 0.61
2016-03-31 16.48 6.42 0.61
2015-12-31 16.01 6.74 0.59
2015-09-30 15.39 3.22 0.61
2015-06-30 14.52 3.25 0.55
2015-03-31 14.44 3.67 0.54
2014-12-31 14.29 3.71 0.54
2014-09-30 14.25 4.19 0.46
2014-06-30 14.20 3.86 0.47
2014-03-31 14.11 3.56 0.44
2013-12-31 14.22 3.68 0.41
2013-09-30 14.53 4.64 0.58
2013-06-30 14.39 3.05 0.58
2013-03-31 14.79 2.86 0.65
2012-12-31 15.76 2.16 0.71
2012-09-30 16.18 -2.70 0.63
2012-06-30 16.37 -2.25 0.64
2012-03-31 15.90 -3.79 0.62

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • MeVis Medical Solutions has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • MeVis Medical Solutions used its assets more efficiently than the DE Healthcare Services industry average last year based on Return on Assets.
  • MeVis Medical Solutions has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess MeVis Medical Solutions's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
MeVis Medical Solutions has a total score of 6/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

M3V Health

 How is MeVis Medical Solutions's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up MeVis Medical Solutions's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • MeVis Medical Solutions is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • MeVis Medical Solutions's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of MeVis Medical Solutions's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • MeVis Medical Solutions has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from MeVis Medical Solutions Company Filings, last reported 2 months ago.

XTRA:M3V Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 34.70 0.00 5.82
2018-09-30 32.06 0.00 3.48
2018-06-30 37.63 0.00 5.25
2018-03-31 34.88 0.00 6.63
2017-12-31 34.06 0.00 10.32
2017-09-30 32.51 0.00 29.74
2017-06-30 36.86 0.00 28.41
2017-03-31 36.45 0.00 28.65
2016-12-31 37.32 0.00 26.51
2016-09-30 32.89 0.00 24.38
2016-06-30 35.66 0.00 22.88
2016-03-31 34.06 0.00 26.33
2015-12-31 33.73 0.00 25.62
2015-09-30 34.58 0.00 22.04
2015-06-30 33.01 0.00 21.56
2015-03-31 30.95 0.00 18.96
2014-12-31 30.27 0.00 17.58
2014-09-30 30.14 0.00 15.52
2014-06-30 28.34 0.00 15.09
2014-03-31 27.14 0.00 13.05
2013-12-31 26.45 0.00 13.45
2013-09-30 25.72 0.02 11.71
2013-06-30 24.32 0.03 9.57
2013-03-31 23.57 0.05 8.63
2012-12-31 22.77 0.06 8.67
2012-09-30 21.13 0.07 9.74
2012-06-30 21.42 0.09 9.08
2012-03-31 20.80 0.10 7.80
  • MeVis Medical Solutions has no debt.
  • MeVis Medical Solutions had no debt 5 years ago.
  • MeVis Medical Solutions has no debt, it does not need to be covered by operating cash flow.
  • MeVis Medical Solutions has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess MeVis Medical Solutions's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. MeVis Medical Solutions has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

M3V Dividends

 What is MeVis Medical Solutions's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from MeVis Medical Solutions dividends. Estimated to be 3.15% next year.
If you bought €2,000 of MeVis Medical Solutions shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate MeVis Medical Solutions's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate MeVis Medical Solutions's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
XTRA:M3V Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Healthcare Services Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 1.5%
Germany Market Average Dividend Yield Market Cap Weighted Average of 328 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

XTRA:M3V Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2021-09-30 0.95 1.00
2020-09-30 0.95 1.00
2019-09-30 0.95 1.00
XTRA:M3V Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2017-08-22 0.000 0.000
2017-02-21 0.000 0.000
2017-01-23 0.000 0.000
2016-10-17 0.000 0.000
2015-04-30 0.040 0.161
2015-01-15 0.040 0.216

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as MeVis Medical Solutions has not reported any payouts.
  • Unable to verify if MeVis Medical Solutions's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of MeVis Medical Solutions's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as MeVis Medical Solutions has not reported any payouts.
Future Payout to shareholders
  • Dividends after 3 years are expected to be covered by earnings (2x coverage).
X
Income/ dividend checks
We assess MeVis Medical Solutions's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can MeVis Medical Solutions afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. MeVis Medical Solutions has a total score of 1/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

M3V Management

 What is the CEO of MeVis Medical Solutions's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Marcus Kirchhoff
COMPENSATION €248,834
TENURE AS CEO 7 years
CEO Bio

Mr. Marcus Kirchhoff has been the Chief Executive Officer, Chairman of the Board and Member of the Executive Board at MeVis Medical Solutions AG since March 1, 2012. Mr. Kirchhoff serves as Vice President and General Manager of Software Solutions at Varex Imaging Corporation. He has extensive experience in leading positions with large international IT companies. He spent 10 years with GE Healthcare in a variety of leadership roles, including Regional Sales Director and modality leader for Imaging & Information Systems in Central Europe. He received a master degree in business administration from the University of Applied Sciences in Bielefeld, Germany form 1992 to 1996.

CEO Compensation
  • Marcus's compensation has been consistent with company performance over the past year.
  • Marcus's remuneration is about average for companies of similar size in Germany.
Management Team

Marcus Kirchhoff

TITLE
Chairman of the Executive Board & CEO
COMPENSATION
€249K
TENURE
7 yrs

Robert Hannemann

TITLE
CFO & Member of Executive Board
COMPENSATION
€198K
Board of Directors Tenure

Average tenure of the MeVis Medical Solutions board of directors in years:

2
Average Tenure
  • The average tenure for the MeVis Medical Solutions board of directors is less than 3 years, this suggests a new board.
Board of Directors

Kim Honeysett

TITLE
Chairman of Supervisory Board
AGE
46
TENURE
2 yrs

Clarence Verhoef

TITLE
Deputy Chairman of Supervisory Board
AGE
63
TENURE
2 yrs

Matt Lowell

TITLE
Member of the Supervisory Board
TENURE
2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess MeVis Medical Solutions's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. MeVis Medical Solutions has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

M3V News

Simply Wall St News

M3V Company Info

Description

MeVis Medical Solutions AG develops, markets, and sells software for analyzing and evaluating image data to equipment manufacturers of medical devices and providers of medical IT platforms in the United States and Europe. The company's clinical focuses are image-based early detection and diagnosis of epidemiologically important diseases, such as breast, lung, prostate, and colon cancers, as well as neurological disorders. It operates in two segments, Digital Mammography and Other Diagnostics. The Digital Mammography segment develops and markets software products, which support breast diagnostic imaging and intervention. This segment also offers software applications for digital mammography, such as ultrasound, magnetic resonance imaging, and tomosynthesis. The Other Diagnostics segment provides digital radiology products, including magnetic resonance imaging and computer tomography for diseases, such as lung, prostate, and intestinal disorders, as well as general image-based analysis and diagnostics of radiology images. Its services are also used for lung diagnostics and general analysis of MR-image data; and technical visualization, which are used in training, for publication, presentations, and research purposes. This segment also provides interactive online training to enhance the diagnostic capabilities of clinical end customers. The company was founded in 1992 and is based in Bremen, Germany. MeVis Medical Solutions AG is a subsidiary of Varex Imaging Deutschland AG.

Details
Name: MeVis Medical Solutions AG
M3V
Exchange: XTRA
Founded: 1992
€54,964,000
1,820,000
Website: http://www.mevis.de
Address: MeVis Medical Solutions AG
Caroline-Herschel-Strasse 1,
Bremen,
Bremen, 28359,
Germany
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
DB M3V Registered Shares Deutsche Boerse AG DE EUR 16. Nov 2007
XTRA M3V Registered Shares XETRA Trading Platform DE EUR 16. Nov 2007
LSE 0HI7 Registered Shares London Stock Exchange GB EUR 16. Nov 2007
Number of employees
Current staff
Staff numbers
88
MeVis Medical Solutions employees.
Industry
Health Care Technology
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/03/25 21:12
End of day share price update: 2019/03/25 00:00
Last estimates confirmation: 2019/02/28
Last earnings filing: 2019/02/26
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/09/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.